To review evolving hemodynamic approaches aimed at optimizing septic shock management while limiting complications, particularly focusing on the integration of multimodal therapies.
Key Findings:
Septic shock is driven by multiple pathophysiologic mechanisms leading to vasodilation, including inflammatory mediators and autonomic dysfunction.
Current guidelines recommend at least 30 mL/kg of intravenous crystalloid for fluid resuscitation, with balanced crystalloids preferred.
Norepinephrine is the first-line vasopressor, with vasopressin as a second-line agent, though evidence for adjunct therapies remains mixed.
Early multimodal vasopressor therapy is gaining interest but lacks strong evidence for mortality benefit, highlighting the need for further research.
Emerging biomarkers and AI tools may help personalize treatment, but many strategies are still supported by weak to moderate evidence.
Interpretation:
The review highlights the complexity of septic shock management and the critical need for individualized, evidence-based approaches to improve patient outcomes.
Limitations:
Many strategies are supported by weak to moderate evidence, such as the mixed results from trials on fluid resuscitation and vasopressor use.
Observational findings may be confounded and not indicative of causality, necessitating caution in interpretation.
There is a pressing need for larger randomized trials to clarify optimal treatment approaches and validate emerging strategies.
Conclusion:
Future research should integrate physiologic monitoring, biomarker-guided therapy, and multimodal vasopressor strategies, focusing on specific patient populations to enhance septic shock management.
These 10 states posted some of the lowest 2026 Medicare practice expense GPCI among states that CMS treats as a single statewide locality, with broader price levels and selected malpractice or tax indicators adding context.
